Stoke Therapeutics, Inc. STOK Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$6.89M+92.3% | -$88.98M+15.0% | -$104.7M-3.6% | -$101.07M-17.8% | ||
| $1.77M-18.7% | $2.18M-11.8% | $2.47M+59.7% | $1.55M+58.7% | ||
| $32.24M+17.4% | $27.47M+8.8% | $25.26M+10.5% | $22.85M+38.9% | ||
| —— | -$86.85M-7.1% | -$81.07M-154% | -$31.87M+52.4% | ||
| $670K+230% | $203K-87.4% | $1.62M-59.2% | $3.96M+230% | ||
| -$195.91M-80.9% | -$108.29M-202% | $105.95M— | —— | ||
| $97.39M-25.7% | $131.09M+147% | $53.01M+14.2% | $46.41M+3,514% | ||
| -$44.66M+29.4% | -$63.23M-179% | $79.97M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Stoke Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.